晚期肺腺癌个体化疗疗效预测因子分析  

Predictive Factors for Customizing Chemotherapy on Advanced Lung Adenocarcinoma

作　　者：徐虹[1] 梅家转[1] 

机构地区：[1]南方医科大学附属郑州人民医院肿瘤内科,郑州450003

出　　处：《肿瘤防治研究》2016年第7期633-637,共5页Cancer Research on Prevention and Treatment

基　　金：郑州市科技领军人才项目(121PLJRC532)

摘　　要：尽管分子靶向治疗能够显著提高晚期肺腺癌患者的生存期和生活质量,然而仍有大多数晚期肺腺癌患者因个体差异性或经济因素未能接受靶向治疗,只能选择规范化一线化疗,化疗方案主要是铂类为基础的两药联合化疗。此外,铂类为基础的化疗方案也是表皮生长因子受体基因(EGFR)突变患者靶向治疗失败后的常规治疗选择。研究发现,晚期肺腺癌患者化疗疗效的预测因子有铂类的耐药基因如核苷酸切除修复交叉互补基因1(ERCC1)、乳腺癌易感基因1(BRCA1)、紫杉类的耐药基因如β-微管蛋白Ⅲ(TUBB3)等,EGFR也可能是化疗疗效的预测因子。本文将就晚期肺腺癌个体化疗疗效的预测因子及其分子机制作一综述。We all know that molecular targeted therapy could significantly improve the survival and quality of life of the patients with advanced lung adenocarcinoma.Nevertheless,most patients with advanced lung adenocarcinoma still receive standard first-line chemotherapy treatment because of individual difference or economic factors,and their best therapeutic option is platinum-based chemotherapy.Moreover,the platinumbased chemotherapy is the standard second-line treatment after progression to an EGFR-inhibitor in EGFRmutated patients currently.Several potential markers,such as excision repair cross-complementing 1（ERCC1） and breast cancer susceptibility gene 1（BRCA1） associated with resistance to platinum,class Ⅲbeta-tubulin（TUBB3） associated with resistance to paclitaxel,have been investigated to predict the outcome of platinum-based chemotherapy.Epidermal growth factor receptor（EGFR） could also provide predictive information to customized chemotherapy.This paper will draw a summary on the predictive factors and the molecular mechanism for customizing chemotherapy on advanced lung adenocarcinoma patients.

关 键 词：肺腺癌 耐药基因 表皮生长因子受体基因(EGFR) 化疗 预测因子 

分 类 号：R734.2[医药卫生—肿瘤]